MarketCap
Facebook
X
Telegram
QIAGEN N.V. General and Administrative Expenses | QGEN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126 M | 113 M | 119 M | 130 M | 128 M | 112 M | 112 M | 141 M | 200 M | 129 M | 104 M | 127 M | 199 M | 152 M | 186 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 104 M | 139 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
3.23 M | $ 1.69 | 0.6 % | $ 4.93 M | USA |
 |
Myriad Genetics
MYGN
|
257 M | $ 6.03 | 3.52 % | $ 558 M | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 2.25 | 6.64 % | $ 675 M | USA |
 |
Neuronetics
STIM
|
31.5 M | $ 2.26 | 7.11 % | $ 149 M | USA |
 |
Agilent Technologies
A
|
1.71 B | $ 175.77 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 357.54 | 3.52 % | $ 17.7 B | USA |
 |
Fulgent Genetics
FLGT
|
117 M | $ 20.23 | 0.65 % | $ 623 M | USA |
 |
Guardant Health
GH
|
211 M | $ 173.31 | 2.5 % | $ 21.7 B | USA |
 |
Accelerate Diagnostics
AXDX
|
21.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 328.03 | -0.28 % | $ 27.3 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 99.94 | 0.14 % | $ 6.74 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 666.34 | -0.24 % | $ 34.3 B |  Schweiz |
 |
ENDRA Life Sciences
NDRA
|
3.72 M | $ 4.82 | 0.42 % | $ 3.79 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 16.7 | 0.63 % | $ 2.14 B | USA |
 |
Neogen Corporation
NEOG
|
245 M | $ 12.22 | 0.21 % | $ 2.66 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 22.54 | 2.78 % | $ 505 M | USA |
 |
Natera
NTRA
|
1.18 B | $ 404.77 | 0.2 % | $ 55.3 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
126 M | $ 11.74 | -0.68 % | $ 123 M |  China |
 |
OPKO Health
OPK
|
223 M | $ 1.63 | 1.23 % | $ 1.22 B | USA |
 |
Trinity Biotech plc
TRIB
|
28.8 M | $ 7.3 | -0.06 % | $ 2.62 B |  Irlanda |
 |
T2 Biosystems
TTOO
|
24.8 M | - | -39.35 % | $ 313 K | USA |
 |
Bioventus
BVS
|
314 M | $ 14.75 | -1.44 % | $ 983 M | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Precipio
PRPO
|
9.45 M | $ 19.5 | -2.55 % | $ 31.3 M | USA |
 |
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
RadNet
RDNT
|
1.82 M | $ 69.9 | -0.63 % | $ 5.26 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
628 M | $ 26.55 | -1.28 % | $ 25.2 B |  Niderland |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 7.46 | -0.67 % | $ 311 M | USA |
 |
Sotera Health Company
SHC
|
253 M | $ 18.35 | 1.35 % | $ 5.21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.73 B | $ 684.39 | 1.57 % | $ 258 B | USA |
 |
Twist Bioscience Corporation
TWST
|
247 M | $ 145.39 | 3.91 % | $ 8.7 B | USA |
 |
Celcuity
CELC
|
27.2 M | $ 65.75 | 0.76 % | $ 3.07 B | USA |
 |
VolitionRx Limited
VNRX
|
9.46 M | $ 0.18 | 0.83 % | $ 22.6 M |  Singapore |
 |
Waters Corporation
WAT
|
240 M | $ 456.36 | 0.39 % | $ 27.2 B | USA |
 |
Exagen
XGN
|
46.6 M | $ 7.44 | 2.34 % | $ 160 M | USA |
 |
Quotient Limited
QTNT
|
42.1 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
56.8 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
547 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K |  Israel |
 |
Castle Biosciences
CSTL
|
229 M | $ 32.84 | -0.73 % | $ 952 M | USA |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
19.8 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
5.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
57.1 M | - | - | $ 1.49 B | USA |